KEZAR LIFE SCIENCES, INC.

Consensus Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.7657 ^USD	-0.30%		-0.91%	-19.18%

May. 09	Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 14	Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Kezar Life Sciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ab546970b9c93b9edb1883318b72b532.X2Url-PMwNEIPctJTbL4NfEBChc8vpwATsCl9mrI0NA.PQwZ5YqD-bhMa_0gOvCuf59EX0V20c5BJYb1kiC56YRmNAbAm_Swg1B2vA~108ce02115d77410aca6a35446db57ed

Analyst Recommendations on Kezar Life Sciences, Inc.

Wells Fargo Adjusts Price Target on Kezar Life Sciences to $2 From $4, Maintains Equal-Weight Rating	Nov. 14	MT
JonesTrading Downgrades Kezar Life Sciences to Hold From Buy	23-10-05	MT
HC Wainwright Raises Kezar Life Sciences Price Target to $20 From $18, Maintains Buy Rating	23-09-25	MT
Wells Fargo Downgrades Kezar Life Sciences to Equalweight From Overweight	23-08-11	MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $18 From $19, Maintains Buy Rating	23-08-11	MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $19 From $21, Keeps Buy Rating	23-05-12	MT
Wells Fargo Trims Kezar Life Sciences Price Target to $13 From $14, Maintains Overweight Rating	23-05-12	MT
William Blair Downgrades Kezar Life Sciences to Market Perform From Outperform	23-03-16	MT
Wells Fargo Cuts Price Target on Kezar Life Sciences to $14 From $17, Maintains Overweight Rating	23-01-03	MT
Wells Fargo Adjusts Kezar Life Sciences Price Target to $17 From $13, Maintains Overweight Rating	22-06-28	MT
Wells Fargo Adjusts Kezar Life Sciences' Price Target to $14 from $19, Keeps Overweight Rating	22-05-04	MT
Wall Street Set for Higher Open Ahead of Fed Funds Rate Announcement, ISM's Services Index	22-05-04	MT
HC Wainwright Adjusts Kezar Life Sciences' Price Target to $22 From $20, Keeps Buy Rating	22-03-18	MT
Wells Fargo Starts Kezar Life Sciences at Overweight With $19 Price Target	21-12-08	MT
HC Wainwright Adjusts Price Target on Kezar Life Sciences to $20 from $12, Keeps Buy Rating	21-11-16	MT
KEZAR LIFE SCIENCES : JonesTrading Starts Kezar Life Sciences at Buy With $14 Price Target	21-07-20	MT

More recommendations

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

OUTPERFORM

Number of Analysts

6

Last Close Price

0.7657 USD

Average target price

11.67 USD

Spread / Average Target

+1,423.66%

High Price Target

20 USD

Spread / Highest target

+2,511.99%

Low Price Target

2 USD

Spread / Lowest Target

+161.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Kezar Life Sciences, Inc.

Wells Fargo Securities
JonesTrading Institutional Services
HC Wainwright
William Blair & Co.

Ratings for Kezar Life Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Stock Market
Equities
KZR Stock
Consensus Kezar Life Sciences, Inc.

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW